Figure 3.
Neutralizing activity against SARS-CoV-2 variants
(A) Amino acid substitutions in the S protein of SARS-CoV-2 variants B.1.1.7, B.1.351, P.1, and mink cluster 5 are schematically shown.
(B) IC50 values of mAbs (μg/mL) and plasma samples (dilution) against pseudoviruses with SARS-CoV-2 S variants are summarized with fold change (variant IC50 value/614G IC50 value).
(C) Neutralization of pseudoviruses with SARS-CoV-2 S variants (upper panels) and RBD mutants (lower panels) was examined by mAbs in 293FT/ACE2/TMPRSS2 cells. Data are represented as means ± SD (n = 3).
(D) IC50 values of plasma samples from 14 patients with COVID-19 other than patients A and B were compared between the 614G pseudovirus and pseudoviruses carrying the variant S protein. Statistical analysis was performed using a Wilcoxon matched-pairs signed rank test, and p values are shown.